<DOC>
	<DOC>NCT00399035</DOC>
	<brief_summary>The purpose of this study is to determine if Cediranib when added to chemotherapy is more effective than chemotherapy alone in prolonging life expectancy and slowing disease progression in patients with previously untreated metastatic colorectal cancer.</brief_summary>
	<brief_title>Cediranib (AZD2171, RECENTINâ„¢) in Addition to Chemotherapy in Patients With Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Cediranib</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>Written Informed Consent Carcinoma of the colon or rectum One or more measurable lesions Adjuvant/neoadjuvant therapy within 612 months of study entry Untreated unstable brain or meningeal metastases Specific laboratory ranges Specific cardiovascular problems Participation in other trials within 30 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Colorectal Cancer</keyword>
	<keyword>Cediranib</keyword>
	<keyword>RECENTIN</keyword>
</DOC>